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Background: Although many diseases have been well characterized at the molecular level, the underlying
mechanisms are often unknown. Nearly half of all human genes remain poorly studied, yet these genes may
contribute to a number of disease processes. Genes involved in common biological processes and diseases are
often co-expressed. Using known disease-associated genes in a co-expression analysis may help identify and
prioritize novel candidate genes for further study.
Results: We have created an online tool, called GeneFriends, which identifies co-expressed genes in over 1,000
mouse microarray datasets. GeneFriends can be used to assign putative functions to poorly studied genes. Using a
seed list of disease-associated genes and a guilt-by-association method, GeneFriends allows users to quickly identify
novel genes and transcription factors associated with a disease or process. We tested GeneFriends using seed lists
for aging, cancer, and mitochondrial complex I disease. We identified several candidate genes that have previously
been predicted as relevant targets. Some of the genes identified are already being tested in clinical trials, indicating
the effectiveness of this approach. Co-expressed transcription factors were investigated, identifying C/ebp genes as
candidate regulators of aging. Furthermore, several novel candidate genes, that may be suitable for experimental or
clinical follow-up, were identified. Two of the novel candidates of unknown function that were co-expressed with
cancer-associated genes were selected for experimental validation. Knock-down of their human homologs
(C1ORF112 and C12ORF48) in HeLa cells slowed growth, indicating that these genes of unknown function,
identified by GeneFriends, may be involved in cancer.
Conclusions: GeneFriends is a resource for biologists to identify and prioritize novel candidate genes involved in
biological processes and complex diseases. It is an intuitive online resource that will help drive experimentation.
GeneFriends is available online at: http://genefriends.org/.
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Over the last decade, microarray technology has allowed
researchers to measure gene expression levels across
large numbers of genes simultaneously, identifying genes
and biological processes that are activated or suppressed
under different conditions. Potential biomarkers [1-4]
and genes involved in a number of diseases, such as
cancer, have been identified by microarray analyses [5,6].
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reproduction in any medium, provided the orgreater power and more information can be gained from
existing data. Meta-analyses have been successfully used
to identify new relationships between genes and new
candidate disease-associated genes [7,8]. Microarrays
provide large-scale, genome-wide data, from which coor-
dinated changes in gene expression can be inferred.
These coordinated changes are valuable in understand-
ing the factors involved in disease and the functions of
many poorly studied genes. One of the issues that arises
with these large-scale datasets, however, is that it
becomes harder to interpret the data and identify key
players. For this reason we created a tool to facilitate this
process: GeneFriends.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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which the general behaviour of genes relative to each
other is studied. This makes it possible to uncover gen-
etic modules that are functionally related [9], under the
assumption that those genes active in the same bio-
logical processes are co-expressed. The main theory
behind this approach is that functionally related genes
are more likely to be co-expressed [10-12]. This “guilt-
by-association” concept has already been used to relate
hundreds of unidentified genes to inflammation, steroid-
synthesis, insulin-synthesis, neurotransmitter processing,
matrix remodelling and other processes [7,13]. Some
of the predicted results have been experimentally vali-
dated demonstrating the effectiveness of this approach
[7]. Candidate genes for cancer, Parkinson’s and Schizo-
phrenia have also been identified using this approach
[1,13-15]. Furthermore, it is possible to identify tran-
scriptional modules that may play causative roles in the
disease or process under study [7,8].
The aim of this work was to construct an online tool
that can be used to derive novel candidate genes for fur-
ther studies in aging and complex diseases, in a quick
and intuitive manner. Aging is not considered a disease,
yet older individuals are more susceptible to several
diseases such as Alzheimer’s, Parkinson’s and cancer.
This is one of the reasons why research in this field is
rapidly expanding and several hundreds of genes have
been linked to aging [16]. A major bottleneck in aging/
complex disease research is that it is difficult to deter-
mine the causality of transcriptional alterations. It is
also unclear if the altered expression profile observed
with aging/complex disease consists of one particular
biological module or whether it consists of genes that
act separately from each other. To this end, GeneFriends
outputs transcription factors co-expressed with the genes
supplied by the user.
Underlying GeneFriends is a genome-wide co-expression
map created using over 1,000 mouse microarray data-
sets. We validated our co-expression map by showing
that functionally related genes are more likely to be co-
expressed. We then used GeneFriends to study transcrip-
tional changes with aging, cancer and mitochondrial
disease. Multiple candidate genes associated with cancer
and mitochondrial diseases, including un-annotated and
poorly studied genes, were identified. Two of the novel
candidates of unknown function that were co-expressed
with cancer-associated genes were experimentally vali-
dated by knock-down in HeLa cells which slowed growth,
supporting our predictions. This demonstrates that Gene-
Friends is a useful resource for studying complex diseases/
processes and can infer function of poorly studied genes.
GeneFriends is freely available online to allow researchers
to quickly identify candidate genes co-expressed with their
genes of interest (http://genefriends.org/).Results
GeneFriends: an online tool for the research community
The aim of the project was to create a user-friendly tool,
which can take a list of genes related to a given disease
or process and quickly identify new candidate genes.
Using co-expression profiling the genes are given in rank
order to help prioritize candidates for experimental
follow up. Underlying GeneFriends is a Mus musculus
co-expression map created from 1,678 microarray data-
sets, comprising over 20,000 individual samples from
previously published experiments. To create the co-
expression map we employed a vote counting method.
The co-expression map contains 427.5 million gene
pairs (20,676 x 20,676) arranged in a matrix and given a
score based on how often they are co-expressed across
all microarrays (see Materials and Methods).
The input for GeneFriends is either a single gene or a
list of Entrez or gene symbol identifiers. The output is a
simple, clear list of co-expressed genes, which can be
downloaded or viewed online. GeneFriends has the fol-
lowing functionalities:
1. It searches for co-expressed genes based on a seed
list or a single gene, and provides a ranked list of
significantly co-expressed genes.
2. It identifies the Gene Ontology (GO) terms and
enrichment for the significantly co-expressed genes.
3. It returns a ranked list of significantly co-expressed
transcription factors.
We feel this output will help researchers in various
fields identify interesting genes for follow up studies in a
quick and intuitive manner. To test if this novel tool can
be used to derive biologically-relevant predictions we
tested gene sets related to aging, cancer or mitochondrial
complex I disease. Furthermore, we tested two predicted
novel candidates experimentally, as detailed below.Testing the co-expression map
The biological significance of the co-expression map was
verified using nine genes known to be involved in three
biological processes: cell division cycle, immune re-
sponse and fatty acid metabolism. The top 5% of genes
identified by GeneFriends as co-expressed were analysed
by DAVID [17] to detect enriched biological processes and
functions. The results confirmed that genes co-expressed
were functionally related to either cell cycle (Enrichment
score: 56.5, FDR: 3.0x10-75), immune response (Enrich-
ment score: 14.7, FDR: 7.8x10-13) or fatty acid metabolism
(Enrichment score: 20.98, FDR: 1.2x10-23); detailed
results are included in the supplementary data (Add-
itional file 1). Furthermore, Figure 1 shows the clustering
of the co-expression map’s network, demonstrating that
Figure 1 Gene clustering in the network of co-expressed genes. Each node represents a gene, and connections indicate a co-expression
ratio of at least 80% between gene pairs. Yellow: Cell cycle (Enrichment score: 66, Benjamini: 5.2x10-83); Blue: Extra-cellular matrix, collagen
( Enrichment score: 16, Benjamini: 3.0x10-22); Red: Immune system (Enrichment score: 6, Benjamini: 1.3x10-16); Green: Fatty acid metabolism
(Enrichment score: 16, Benjamini: 1.6x10-23).
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logical processes.
GeneFriends uses a vote-counting method to rank co-
expression. We compared GeneFriends to COXPRESSdb
[9], which utilizes the more commonly used correlationvalue (Pearson or Fisher). To do so we selected 3 genes
with known functions and retrieved output from both
tools and used DAVID to determine enriched categories.
The results show similar categories and scores although
the overlap in the specific genes can vary (Additional
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factors present in the top 1000 co-expressed genes from
GeneFriends and COXPRESSdb the results are similar.
This demonstrates that our approach is similar to using
Pearson correlation to create a co-expression map.
Candidate gene prediction from process/disease
gene lists
We used GeneFriends to identify novel candidate genes
associated with specific processes or diseases. The
results show the numbers of times each of the 20,676
genes in the co-expression map were "friends" with
genes in the disease gene seed and corresponding p-
values indicate the statistical significance of the co-
expression (see Materials and Methods). The p-value is
calculated based on the number of seed genes a given
gene is co-expressed with and the total number of genes
it is co-expressed with (Materials and Methods). DAVID
was used to interpret the broader biological significance
of the results. All genes with a co-expression p-value
<10-6 were classified using the default settings in
DAVID. This is a stringent cut-off since using a Bonfer-
roni correction for multiple testing results in: 0.05/
20,677 > 10.
-6
Aging-related gene prediction and putative
transcriptional mechanisms
GeneFriends was used to identify genes related to aging.
A seed list of genes known to be consistently over-
expressed with age in mammals was used [18]. In total,
1119 genes were co-expressed with the aging seed list at
p <10-6; Table 1 shows the top 25 genes. Many of these
genes have been associated with age-related diseases.
Several other genes that have been shown to play a role
in aging such as lysosomal-associated membrane
protein-2 Lamp2 [19] (p = 5.68-30), Fas [20] (p = 2.70-31)
and growth hormone receptor Ghr [21] (p = 1.34-19) also
showed a significant co-expression. Anxa2, Anxa3 and
Anxa4 also show a low p-value (p < 10-25) as well as
several S100 calcium binding proteins which have been
shown to interact with annexins [22].
The most significantly over-represented functional
clusters were inflammatory response (enrichment score
(ES) = 24.13, FDR= 1.97x10-18), vasculature development
(ES = 10.18, FDR= 2.31x10-8) and lysosome (ES = 9.00,
FDR= 2.25x10-8). Since most of the genes in the seed list
were classified in the categories related to the immune
system, it was unsurprising to find similar results for the
co-expressed genes.
Eighty genes from the initial 181 genes in the aging
seed list showed a co-expression p-value <10-6, suggest-
ing the presence of shared transcriptional modules. In
order to investigate the underlying transcriptional
mechanisms that may induce this expression profile weused the co-expressed transcription factor (TFs) results
from GeneFriends. Table 2 shows the 20 most signifi-
cantly co-expressed TFs with aging. The most signifi-
cant TFs identified were C/ebpα, C/ebpβ and C/ebpδ
(Table 2). Interestingly, these TFs show co-expression
(i.e., in top 5% of co-expressed genes) with a significant
proportion of the genes co-expressed with the aging seed
list: 477 out of 1119 genes (p-value < 10-100) for all 3 TFs
and 730 out of 1119 (p-value < 10-100) were co-expressed
with at least 2 out of 3 C/epβ genes.
Since these TFs are co-expressed with the aging-
related genes it was expected that these genes, at least in
part, would be regulated by the co-expressed TFs.
Therefore, they would share transcription factor binding
sites (TFBS) for these TFs. To identify over-represented
binding motifs in the genes co-expressed with the aging
genes (p-value < 10-6) we employed factorY [23]. For the
aging gene set this revealed Nfkb as the most significant
result (Additional file 4). Some of the TFBS identified
have co-expressed genes with the aging seed list such
as NFKB1 (pTFBS =1.48 x10
-5, pCoexpress = 4.44 x10
-9), the
C/ebp (pTFBS = 6.95 x 10
-3, pCoexpress =7.9 x 10
-34) genes
and IRF1 (pTFBS = 5.8 x 10
-4, pCoexpress =8.17x10
-23) genes
(Additional file 4). However, TFBS for Isre, Nfkb2 (p65)
and Sp1 were identified as over-represented but not co-
expressed and many co-expressed TFs did not have
over-represented binding sites.
Cancer-related gene prediction
A list of 45 cancer-related genes was used as seed list for
GeneFriends (see Materials and Methods). DAVID ana-
lysis identified Cell cycle (ES = 58.84, FDR = 2.9x10-77)
and DNA replication/repair (ES = 34.99, FDR=6.0x10-51)
as the most significant over-represented categories for
cancer-related co-expressed genes. This is expected given
the fact that cancer arises from the uncontrolled division
of cells. Table 3 shows the top 10 co-expressed genes.
From the original seed list only 6 genes pass the
p <10-6 threshold co-expressed with the entire set of
cancer genes, which could be due to the heterogeneity
of cancer etiology. However, there were several signifi-
cantly co-expressed genes, not included in the seed list,
that have previously been associated with cancer. For ex-
ample, Cdc25a, Cdc25b and Cdc25c, members of the
Cdc25 family, are significantly co-expressed (p < 10-6)
with the cancer-related genes.
There were a high number of significantly co-
expressed centromeric proteins co-expressed with the
cancer seed list. These proteins play a role in chromo-
some segregation and incorrect segregation of chromo-
somes during the cell cycle can lead to cancer [24].
Cep152 is involved in centriole duplication [25]. Cenpp,
as well as CenpN/F/H/J/I/C1/T/K/M/E/Q/A/L, are all
co-expressed significantly with the cancer seed list
Table 1 Top 25 genes co-expressed with aging related
genes
Gene Previous association evidence Reference
Thbs1 Plays a role in platelet aggregation,
angiogenesis and tumorigenesis
[57-59]
Ctsh No previous associations
2310043n10rik No previous associations
Sat1 Induction has been suggested as a
therapeutic strategy for treating
colorectal cancer
[60]
Tcn2 No previous associations
Pgcp No previous associations
D12ertd647e No previous associations
Cd74 Initiates signalling leading to cell
proliferation and survival
[61]
B2m B2m deficient mice suffer from
tissue iron overload
[62]
Tgm2 Overexpression increases apoptosis
in neuroblastoma cells
[63]
Implicated in fibrosis,
neurodegenerative and celiac disease
[64]
Rarres2 No previous associations
Anxa1 Plays an important role in
anti-inflammatory signalling, apoptosis
and proliferation
[65,66]
Il10rb No previous associations
Ctsc Mutations cause Papillon-Lefevre Disease [67,68]
Lipa Mutations can cause Cholesteryl ester
storage disease and Wolman disease
[69]
IL3ra1 No previous associations
Lgals3bp Associated with cancer and metastasis [70]
Pros1 Associated with Thrombosis [71,72]
Fcgr2b No previous associations
Scd1 Plays an important role in body weight
regulation and development of obesity
[73]
Ifi35 No previous associations
Ctla2b No previous associations
Cebpd Implicated in adipocyte differentiation,
learning and memory, mammary
epithelial cell growth control.
[74-76]
Loss of Cebpd leads to chromosome
instability
[77]
Fcgrt No previous associations
H2-t23 No previous associations
For a full list refer to Additional file 3.
Table 2 Top 10 co-expressed transcription factors with
genes increased in expression with aging
Transcription
factor
p-value Gene Name
C/ebpδ 7.90x10-34 CCAAT/enhancer binding
protein (C/EBP), delta
C/ebpα 1.19x10-30 CCAAT/enhancer binding
protein (C/EBP), alpha
C/ebpβ 3.78x10-30 CCAAT/enhancer binding
protein (C/EBP), beta
Creg1 1.70x10-29 cellular repressor of
E1A-stimulated genes 1
Nfe2l2 1.17x10-28 nuclear factor, erythroid
derived 2, like 2
Irf7 8.04x10-26 interferon regulatory factor 7
Klf2 1.86x10-23 Kruppel-like factor 2 (lung)
Irf1 8.17x10-23 interferon regulatory factor 1
Ostf1 1.96x10-22 osteoclast stimulating factor 1
Atf3 2.09x10-22 activating transcription factor 3
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complex. This complex is required for proper kineto-
chore function and mitotic progression and its disrup-
tion can lead to incorrect chromosome alignment and
segregation that preclude cell survival despite continued
centromere-derived mitotic checkpoint signalling
[26,27]. Plk1, Aurka, Aurkb and Cdca8 are in the top 50co-expressed genes, these play an important role in can-
cer formation [28,29].
Several un-annotated genes (Bc055324, E130303B06Rik,
4930547N16Rik, F730047E07Rik, 1110034A24Rik, and
4632434I11Rik) were co-expressed with the cancer-
related genes, suggesting these genes might play a role in
occurrence or pathophysiology of cancer. One of these
un-annotated genes, Bc055324, is a predicted protein
coding gene, which has a high co-expression ratio of
more than 0.7 with the cancer genes Rad51 and Ccdc6
[30], indicating this gene is increased in expression in
>70% of the cases when Rad51 is increased in expression.
Many other cancer-related genes such as Brca1 and
Brca2 also show a strong co-expression with the
Bc055324 gene (Additional file 6). All genes co-
expressed with Bc055324 show enrichment for the cell
cycle (ES = 52, FDR=1.7x10-74). A BLAST analysis of the
protein sequence shows no significant homology to other
Mus musculus proteins. Similar sequences, however, are
found in a large number of different multi-cellular spe-
cies such as Gallus gallus, Bos taurus and Homo sapiens
and there also is a significantly similar gene present in
Arabidopsis thaliana, suggesting it is conserved in plants
as well, indicating it plays a functional role.
Validating the role of C1ORF112 and C12ORF48 in growth
of cancer cells
To test our predictions, we employed siRNAs to knock
down the human homologs of Bc055324 (C1ORF112)
and 4930547N16Rik (C12ORF48) in the widely-used
HeLa cancer cell line. These two genes were selected for
validation because they are co-expressed with genes
involved in the cell cycle (Additional file 6), so
Table 3 Top 10 genes co-expressed with cancer-related
genes
Gene Previous association evidence Reference
Nfkbil2 Confers resistance to DNA
damaging agents and is a
component of the replication
stress control pathway
[78]
Chtf18 Involved in checkpoint
response and chromosome
cohesion
[79]
Cdc25c Over expression associated
with poor prognosis of cancer
[40]
Cdc7 Effective in inhibition of
cancer growth
[80]
E130303b06rik No previous associations
Cep152 Involved in centriole duplication [25]
Bc055324 No previous associations
Cenpp Required for proper kinetochore
function and mitotic progression
[81]
Anln Increased in expression in lung
carcinogenesis and suggested
as target
[82]
Hirip3 No previous associations
For a full list refer to Additional file 5.
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Furthermore, validated siRNAs are available (see Materi-
als and Methods) for these genes. The results show
that the growth rate of the cancer cells is significantly
lower when either C1ORF112 or C12ORF48 are knocked
down (Figure 2). These results support our predic-
tions and demonstrate that C1ORF112 and C12ORF48
are functional.
Mitochondrial complex I disease-related gene prediction
All 10 genes in the seed list of mitochondrial complex I
disease genes were significantly co-expressed with each
other. This was the strongest co-expression amongst all
disease gene seed lists tested, indicating they are
involved in the same process and are tightly regulated
(Additional file 7). Table 4 shows the top 10 co-
expressed genes with the seed list. The results included
a number of genes that have been associated with several
diseases amongst which Alzheimer’s and Parkinson’s
disease. Not surprisingly, DAVID analysis identified,
Mitochondrion (ES = 210.25, FDR= 3.6x10-250), Cellular
respiration (ES = 18.25, FDR= 5.9x10-23) and Oxidore-
ductase activity, acting on NADH (ES = 14.49, FDR= 2.3
x10-22), as the most significant functional clusters.
The co-expressed genes include several mitochondrial
complex I genes (not in seed list), multiple cytochrome c
proteins and genes involved in the ATP synthase com-
plex. Furthermore, there are approximately 50 poorly/
un-annotated genes co-expressed. A pseudo gene,
3000002C10Rik, shows a co-expression ratio of >0.5 with512 genes. Classification of these 512 genes using DAVID
results in an enrichment score of 53.7 (FDR=2.9x10-70)
for mitochondrial genes. Therefore, 3000002C10Rik
may play a biologically relevant role in mitochon-
drial processes.
Predicting functions of un-annotated genes
To investigate if it is possible to predict or estimate a
given gene’s function based on its co-expression pattern
we inspected a selection of un-annotated genes. Using
DAVID, the functional categories for the top 5% co-
expressed genes were obtained. Table 5 shows the func-
tional categories for the un-annotated genes with the
highest significance value. While some of the categories
identified are broad, others are more specific. Together
with the results for C1ORF112 or C12ORF48, these
results show that it is possible to use GeneFriends to
infer gene function.
Discussion
GeneFriends: a genetics and genomics tool for the
research community
Genefriends is freely available online (http://genefriends.
org/) and is an intuitive tool, which can be used to iden-
tify the genes co-expressed from a user supplied gene
list. This simple, yet powerful new tool can be a valuable
resource for genome interpretation, annotation, mouse
genetics, functional genomics and transcriptional regula-
tion. It may also be useful to develop network analyses
of mouse genes in a variety of studies.
We tested GeneFriends to determine whether it can
give biologically relevant data. We also demonstrated
how GeneFriends can be used to quickly identify inter-
esting gene targets for follow up studies. Furthermore,
we experimentally validated two un-annotated genes co-
expressed with a cancer seed list. Below we discuss the
findings we have obtained from our example analyses
and the biological relevance of our results.
Validation of the co-expression map
The main assumption made when constructing our
mouse co-expression map is that co-expressed genes
tend to be involved in the same biological processes.
Our results clearly support this, showing that genes
known to play a role in certain biological processes such
as immune system, cell cycle and lipid metabolism are
co-expressed and form clusters in the co-expression net-
work (Figure 1). Different clusters show different
strengths of co-expression, therefore the effectiveness of
the gene set analyses may vary. However, there is a high
degree of functional coherence between co-expressed
genes showing that our co-expression map can be used
to obtain biologically-relevant information.
Figure 2 Knock-down of candidate cancer related genes slows growth of HeLa cells. a. Cell counting assay for the knock down of the
human homolog gene of Bc055324 (C1ORF112). b. Cell counting assay for the knock down of the human homolog gene of 4930547N16Rik
(C12ORF48). Error bars indicate the standard deviation. Negative control contains siRNA's targeting non-mammalian genes. Positive control
contains siRNA's inducing apoptosis.
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used a vote counting approach, which is a standard
meta-analysis technique, to build our co-expression map
[31]. The aim of this approach is to emphasize sensitiv-
ity. This is particularly important when combining large
and diverse datasets and has been shown to increase
sensitivity when studying aging, for example [18].
From a technical point of view, we aimed to include asmuch data as possible and because of the technical
implications accompanied by this the vote counting
method is more efficient and has faster run times than
other methods.
Co-expression analysis of genes associated with aging
Using a guilt-by-association method we identified candi-
date genes related to seed lists of genes associated with
Table 4 Top 10 genes co-expressed with mitochondrial
complex I disease related genes
Gene Previous association evidence Reference
Atp5j Risk factor for ischemic heart
disease end-stage renal disease
[83]
Cox7a2 No previous association evidence
Ndufa1 No previous association evidence
Ndufb7 No previous association evidence
Colx7c No previous association evidence
Cox5b Interacts with the human
androgen receptor
[84]
Atp5f1 No previous association evidence
D830035I06/Atp5k Atp5k has been associated with
atherosclerosis
[85]
Deb1 C.elegans mutants were paralyzed
and had disorganized muscle
[86]
Ndufb6 No previous association evidence
For a full list refer to Additional file 7.
Table 5 Top functional annotation clusters of the 5%
strongest co-expressed genes with un-annotated genes
Un-annotated
Gene
DAVID Functional
Annotation
ES FDR
0610006I08Rik
Mitochondrion 32.75 1.1x10-40
0610006L08Rik
Disulfide bond/secreted 33.14 3.1x10-38
PeptidaseS1/Chymotrypsin 16.25 1.4x10-20
0610010D20Rik
Peroxisome 21.8 3.8x10-22
Fatty acid metabolism 21.78 1.7x10-22
Drug metabolism/
CytochromeP450
17.94 6.1x10-20
0610031J06Rik
Lysosome 18.59 2.4x10-18
0610037L13Rik
Ribosomal protein 16.97 1.2x10-22
0610037M15Rik
Immune response 24.02 2.0x10-28
0710008K08Rik
Vasculature development 13.26 1.9x10-12
Lung development 12.36 2.4x10-10
Clusters from DAVID with an enrichment score (ES) above 5 are displayed
(10 for 0610010D20Rik). Cluster titles and FDR were selected based on the
most significant annotation within the cluster. For full lists refer to Additional
file 8.
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genes relevant to current theories of aging, e.g. inflam-
mation, but it also identified novel candidates for further
research. C/ebp transcription factors showed the stron-
gest co-expression and are therefore candidate activators
of the altered expression patterns with age. TFBS for C/
ebp genes were identified in the aging genes and there is
some evidence of a transcriptional cascade via SP1 [32].
The two proteins encoded by the C/ebpβ gene are liver
activating protein (LAP) and liver inhibiting protein
(LIP), which have opposing effects [33,34]. The LIP pro-
tein is also capable of inhibiting other C/ebp proteins.
This could explain why C/ebp transcription factors
themselves are not found to be increased/decreased in
expression with age. This could also be due to the fact
that TFs are sometimes expressed at low levels not
detected by microarrays.
Replacement of the C/ebpα gene with C/ebpβ
increases lifespan by 20% [35,36], and may alter the rate
of aging [37], indicating that altering the isoform expres-
sion of these genes can affect lifespan. Moreover, the
life-extending drug rapamycin may affect isoform ratios
of C/ebpβ. Rapamycin has been shown to increase life-
span via the suppression of Mtor [38] which in turn
controls the isoform ratios of C/ebpβ [39]. Therefore,
we speculate that rapamycin may in part exert its life
extending effect through C/ebpβ.
Co-expression analysis of cancer genes and experimental
validation of candidates
We used GeneFriends to identify new candidate genes
for a role in cancer. Many of the cancer genes in the ini-
tial seed list were not present in the results, indicating
they are not co-expressed with each other. This may bedue to the fact that this set of cancer genes includes
both oncogenes and tumour suppressor genes which are
not expected to be co-expressed. Also cancer can arise
through different mechanisms. Therefore the genes
identified as co-expressed in this study are likely
involved in common pathways leading to cancer, or are
at least triggered by transformation.
Genes that are co-expressed with several oncogenes
may prove to be useful targets in countering the prolifer-
ating effect of these genes in tumours. Examples of such
genes that are already being studied are Cdc7 and Cdc25
genes, both of which were identified as co-expressed in
our study. Cdc25 has been suggested as a therapeutic
cancer target and on-going studies in this direction have
shown some level of success [40-43]. Two compounds
that target Cdc7 are currently in phase I clinical trials
[44]. The fact that candidate genes identified by our
method have already been suggested as potential drug
targets shows that GeneFriends can be useful for the
identification of candidate targets for cancer studies.
Bc055324 is one of the poorly annotated genes that is
strongly co-expressed with a large number of cancer
genes. Knock-down of the human homolog, C1ORF112,
in HeLa cells diminishes cell growth, which adding the
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(http://www.europhenome.org/), demonstrates that this
gene is functional. Further studies of this gene in the
context of cell cycle regulation, development and cancer
are warranted. These results show that GeneFriends can
indeed be used to identify novel targets for particular
diseases. In addition it confirms that the functional
enrichment of co-expressed genes can give indications
about an un-annotated gene's function. The other un-
annotated gene co-expressed with cancer we tested was
4930547NRik (C12ORF48). C12ORF48 was recently
shown to be over-expressed in pancreatic ductal adeno-
carcinoma cells [46] and in other aggressive and
therapy-resistant malignancies [46]. In line with our
findings in HeLa cells, knock down of C12ORF48 signifi-
cantly suppressed PDAC cell growth [46].
Co-expression analysis of mitochondrial I complex
disease genes
Mitochondrial complex I diseases include isolated com-
plex I deficiency, which is the most common enzymatic
defect of the oxidative phosphorylation disorders and
can cause a wide range of clinical disorders [47,48].
These include macrocephaly with progressive leukody-
strophy, nonspecific encephalopathy, cardiomyopathy,
myopathy, liver disease, Leigh syndrome, Leber heredi-
tary optic neuropathy, and some forms of Parkinson’s
disease [49-51]. Mutations in the nuclear encoded mito-
chondrial genes have been associated with several path-
ologies [52,53]. However, half of the patients with
mitochondrial complex I (CI) deficiencies lack mutations
in any known CI subunit suggesting that yet unidentified
genes crucial for maturation, assembly, or stability of CI
may be involved in these diseases [53]. We identified
several un-annotated genes that show a strong co-
expression with the mitochondrial disease gene set. As
most of the other co-expressed genes encode mitochon-
drial proteins, these un-annotated genes most likely also
encode mitochondrial proteins. This is further supported
by the fact that a number of these un-annotated genes
have been shown to be active in the mitochondria in an-
other large-scale study [54]. Some of these genes could
be responsible for the CI deficiency phenotype and are
therefore promising candidates for further studies.
Conclusions
In this study we created a tool that identifies co-
expressed genes from a user’s seed list. Moreover, it
returns the GO term enrichment of this list as well as a
separate list of the co-expressed transcription factors.
This allows novel candidate genes to be quickly identi-
fied for follow up studies. GeneFriends employs a
biologically-relevant co-expression map and a guilt-by-
association method to identify novel candidate genes forcomplex diseases/processes. We demonstrated the bio-
logical relevance of this tool by analysing aging, cancer
and mitochondrial I complex deficiency seed lists. Fur-
thermore, we experimentally validated two un-annotated
candidate genes co-expressed with cancer-related genes.
We also demonstrated how GeneFriends can be used to
investigate transcription factors that are co-expressed
with seed genes of interest, helping to elucidate the
regulatory mechanisms. GeneFriends is freely available
online (http://genefriends.org) for other researchers to
identify and prioritize candidate genes to study other
complex diseases and processes.
Methods
Data selection
To create the co-expression map, normalized microarray
data obtained from the GEO database was used [55].
GEO files GSE1 to GSE18120 were downloaded contain-
ing 16,916 datasets in total. From these, 3,850 Mus
musculus datasets containing 64,849 microarrays and
the corresponding annotation files were extracted. As
mouse experiments are generally better controlled than
human studies and there is less variation caused by
genotypic and environmental factors in the mouse, Mus
musculus data was chosen over Homo sapiens to reduce
noise. Using mouse data also allows more datasets, com-
ing from a more diverse set of experiments [18]. This
also potentially allows for the investigation of target
genes in the different mouse models of aging and com-
plex diseases.
All datasets containing annotation files that did not in-
clude gene symbols for at least 90% of the probes
present in the data were removed. All microarray
datasets containing values higher than 25 were log
transformed, under the assumption this data was non-
log-transformed data. To remove poor signal, low quality
or nonsense values up to 1099 datasets containing no
values above 2log(5,000) or one or more values over
2log(20,000,000) were removed. Datasets with no refer-
ence to any annotation file were removed. Even though
it is not feasible for us to perform a comprehensive
evaluation of the quality of the data in each experiment,
a meta-analysis is in its essence a technique to eliminate
poor quality data and hence we are confident that there
are no systematic errors in our analysis that artificially
originate false results. After these steps 1,678 datasets
containing 8,417 different conditions and 21,744 individ-
ual samples remained. The probe IDs were converted
into gene symbols. If multiple probe IDs mapped to the
same gene symbol, they were averaged. Within each
dataset the experimental conditions were manually
determined. Microarrays from individuals under the
same conditions were averaged; in other words, dupli-
cates were averaged. Missing values were ignored as long
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gene symbol was removed.
Constructing the co-expression map
To create GeneFriends we first constructed a genome-
wide co-expression map, using normalized Mus muscu-
lus microarray data from the GEO database. This
describes which genes are related based on how often
they are co-expressed. In total, 1,678 mouse datasets
containing 8,417 different conditions and 21,744 individ-
ual samples met our data selection criteria. To construct
our expression map the different conditions within each
dataset were compared to each other. Since different
datasets contain different probes mapping to different
gene symbols a selection was made. Only those gene
symbols that are present in gene platform file GPL1261
(Affymetrix GeneChip Mouse Genome 430 2.0 Array)
were used. This platform contains 20,676 gene symbols
and is the most common platform used for microarrays
amongst those included in this work. All of these gene
symbols were present in over 850 datasets.
In this work we have used a vote counting approach to
quantify co-expression for approximately 400 million
(20,676*20,676) gene pairs. We used these pairs to estab-
lish if genes were co-regulated; co-regulation being
defined as both genes increasing or decreasing in expres-
sion at least two-fold simultaneously, a standard (even if
arbitrary) measure of differential expression. Then based
on how often gene pairs were co-regulated compared to
how often the single genes showed a two-fold increase
or decrease in expression we calculated a co-expression
ratio, which quantifies how strongly two genes are co-
expressed, for all 20,676*20,676 gene pairs. The number
of times two genes were simultaneously differentially
expressed in the same direction (i.e. relative up or down
regulated) was calculated using the equation:
Ngene1; gene2 ¼
Xx
i¼0
UPgene1; iUPgene2; i
þ
Xx
i¼0
DOWNgene1; i DOWNgene2; i
Where x is the total number of comparisons and
N the number of times two genes are differentially
expressed (in the same direction) simultaneously.
For simplification the terms “UP” and “DOWN” are
used in this formula. The actual directionality of the
change is irrelevant as it is dependent on the direction
of the comparison (i.e. whether one compares group 1
with group 2 or the other way around). Either way the
results will be the same.
To reduce the effects of noise present in microarrays,
an arbitrary two fold cut-off was selected, as is used inthe majority of microarray analyses to indicate differen-
tial expression of genes. The total number of times each
gene was relatively up or down regulated (i.e., >2 fold)
was calculated using the following equation:
Qgene1 ¼
Xx
i¼0
DIFFERENTIALLY EXPRESSEDgene1; i
Where x is the total number of comparisons and
i describes the current comparison between the differ-
ent conditions.
From the values N and Q the co-expression ratio was
deducted. The genes were then ranked based on their N:
Q ratio. A ratio of 0.50 would indicate that if gene 1 is
increased or decreased in expression in 50% of the cases
gene 2 is also increased or decreased in expression. Each
gene pair is present in at least 850 datasets and so the
ratio is based on a large number of measurements.
Testing the co-expression map
To investigate the capacity of the co-expression map to
provide biologically-significant results nine genes known
to play a role in specific biological processes were inves-
tigated: three genes that are known to be active in fatty
acid metabolism: Ppara, Acaa2 and Acadm; three genes
known to be involved in immune response: Cd4, Cd8
and Il10; and three cell cycle genes: Cdc6, Cdc7
and Cdc8. These were selected before the analyses to
reduce biases.
It was expected that genes co-expressed with these
nine genes would be involved in the same biological pro-
cesses; to test this assumption we inspected if any spe-
cific categories were over-represented by these groups of
genes (see below for functional enrichment analysis).
Prediction of novel candidate genes in aging and
complex diseases
In order to identify genes co-expressed with known dis-
ease genes, three disease related gene sets were included.
The first of these was an aging gene set. It consisted of
genes over-expressed with age obtained from a meta-
analysis of aging microarray studies in mice, rats and
humans that revealed several conserved genes increasing
or decreasing in expression with age [18] (Additional file
9). The second gene set included was a set of cancer-
related genes [56] (Additional file 9). This is a manually
curated cancer set that includes only heritable cancer
genes with strong evidence that mutations in these genes
are causative for cancer. The third gene set added
included genes known to cause diseases through mito-
chondrial complex I deficiencies. The genes in this set
contain the nuclear mitochondrial complex I deficiency
genes in the OMIM database (Additional file 9). Gene
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were not included in the analysis.
Using the above seed lists, a "guilt-by-association" ap-
proach was employed to find new potential disease-
related gene targets. In this approach the top 5% most
co-expressed genes with each gene were considered
“friends” of that particular gene. For each of the 20,676
genes we calculated how many times it was “friends”
with the disease related genes. Next, the probability
that a gene was “friends” with this number of disease
genes was calculated, as follows. How often each gene
was “friends” with any other gene was counted, from
which the chance a gene is "friends" with another gene
was calculated:
p ¼ total number of friends with other genes
=total number of genes
Where p is in effect the chance that a particular gene
occurs in the top 5% of a random gene.
We assume the following null hypothesis: The prob-
ability of a gene being a “friend” with one of the n dis-
ease genes equals the probability p of being a “friend”
with a random gene. Then the probability of a gene
being a “friend” with k or more genes from the dis-
ease list can be calculated by using the right-tail of the
binomial distribution.
Pr K >¼ kð Þ ¼
Xn
k¼k
n
k
 
pk 1 pð Þnk
Where Pr(K > = k) is the probability that a gene would
be “friends” with k or more genes in the disease gene
set; k is the number disease gene “friends”; n is the num-
ber of genes in the gene set. When calculating p the
number of occurrences of a gene in the top 5% of all
genes was included. This is necessary since some genes
tend to be co-expressed more often in general than
other genes.
Experimental validation of cancer-related genes Bc055324
and 4930547N16Rik
To test the predictions from the analyses using Gene-
Friends, we took un-annotated genes that were the most
co-expressed with the cancer disease gene list. Validated
siRNAs were available from Qiagen for two the human
homologs of the top un-annotated genes: Bc055324
(C1ORF112) and 4930547N16Rik (C12ORF48). The
experiment was conducted in human HeLa cells using
standard culture conditions. A negative and a positive
control were also included (Qiagen). The positive
control contained a mix of several apoptosis inducing
siRNAs, demonstrating that the transfection was suc-
cessful through elevated cell death. The negative controlconsisted of siRNAs targeting non-mammalian genes.
The full protocol followed for this experiment is
described in Additional file 10.
Gene function enrichment analysis
The Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) [17] was used to identify
enriched functional groups within these genes. The de-
fault settings were used in this analysis. The results were
ranked based on p-value and genes with a p-value <10-6
were selected. This is a stringent cut-off since using
a Bonferroni correction for multiple testing results in:
0.05/20,677 > 10-6. In addition, a randomization test
showed this is a very stringent cut-off in which no false
positives are expected by chance. The test entailed the
construction of several random sets of genes which were
then used to find co-expressed genes. The p-values
found for all results were >10-5, indicating that genes
with a p-value <10-5 are very unlikely false positives.
Next, to understand the significance of the DAVID
enrichment score, 1000 genes were randomly selected
and used as an input for DAVID. This resulted in an
enrichment score of 2.2 with an FDR score of 0.7 for the
most significant category found. The same was done for
smaller numbers resulting in similar scores. This indicates
that the Enrichment scores of >10 and FDR <10-10 are
very significant and cannot be found by random chance.
Benchmarking using our co-expression map and
COXPRESSdb revealed similar results (Additional file 2),
suggesting our co-expression map is not inferior to those
built using correlation measures. Therefore, our work
demonstrates that vote counting is a viable method to
build co-expression maps.
One concern is that some of the genes in functional
categories were assigned based on their expression pat-
tern; if this would be the case it could lead to circular
reasoning. However, an analysis conducted by the
DAVID team shows that less than 1% (116/20676) of the
genes is grouped based solely on their expression pattern
(see Additional file 11 for a list of these genes).
BLAST
A BLAST search was conducted on the Bc055324 gene.
The protein sequence for this gene was recovered from
GenBank version: Bc055324.1. This sequence was PSI-
blasted against the non-redundant protein sequence
database. Then the search was iterated twice including
all sequences recovered in the initial search.
Additional files
Additional file 1: DAVID enrichment scores of 10 selected genes
known to be related to cell cycle, immune response and fatty acid
metabolism.
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Additional file 3: Co-expressed genes with aging related gene seed
list.
Additional file 4: Co-expressed transcription factors with aging
related gene seed list.
Additional file 5: Co-expressed genes with causative cancer gene
seed list.
Additional file 6: Co-expressed genes with Bc055324 and
4930547N16Rik.
Additional file 7: Co-expressed genes with mitochondrial complex I
disease related gene seed list.
Additional file 8: Top 5% co-expressed genes with poorly
annotated genes.
Additional file 9: Seed list containing causative cancer genes and
seed list containing aging related genes.
Additional file 10: Transfection protocol.
Additional file 11: List of DAVID genes of which grouping is solely
inferred from expression pattern.
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